Lasa Supergenerics Ltd. (IN:LASA)
:LASA
Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹11.33
-₹1.79(-6.22%)
At close: 4:00 PM EST
₹11.33
-₹1.79(-6.22%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹15.29
Previous CloseN/A
Volume56.48K
Average Volume (3M)39.13K
Market Cap
₹387.28M
Enterprise Value₹486.84M
Total Cash (Recent Filing)₹6.96M
Total Debt (Recent Filing)₹73.38M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.73
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low debt-to-equity (~0.20) gives the company balance-sheet flexibility to absorb shocks or fund operational fixes without immediate refinancing pressure. Over the next several months this reduces default risk and preserves capacity for restructuring or targeted investments to stabilize operations.
B2B API Manufacturing ModelAs a supplier of APIs and intermediates to formulators and finished-dose manufacturers, the business benefits from durable, contract-driven B2B demand and long customer qualification cycles. This structural role in the pharma supply chain supports recurring orders and stickier revenue once customer relationships are restored.
Prior Cash-generation CapabilityHistorical periods of strong operating cash flow show the business can generate cash when operations and pricing align. That precedent implies management has levers (utilization, yields, cost control) to recover cash generation over months if corrective actions and customer demand improvements occur.
Bears Say
Sharp Revenue DeclineA ~74% revenue collapse materially erodes scale advantages, reduces fixed-cost absorption, and weakens supplier/customer bargaining positions. Over several months this can drive further margin pressure, complicate recovery of utilization, and limit ability to rebuild recurring contract volumes.
Deep Margin Erosion And Persistent LossesSustained deeply negative margins point to structural pricing or cost issues and/or large non-operating charges. Continued losses erode equity and limit reinvestment, increasing the risk that operational fixes will be underfunded and that performance may not normalize without substantive strategic change.
Weak And Inconsistent Cash GenerationNegative OCF (~-81M) and pressured free cash flow reduce internal funding for working capital and capex, forcing reliance on external financing or asset measures. Over a multi-month horizon this raises liquidity and execution risk, making recovery dependent on timely funding or rapid operational improvement.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹15.29 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹387.28M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 76 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on May 29, 2026. The company reported -₹0.83 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.83.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.83 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―